^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial

Published date:
10/01/2021
Excerpt:
From 2015 to 2019, 24 AR+ patients with SGC (23 men; median age 65.8 years) were treated within the study.... All patients received abiraterone 1 g daily plus prednisone 10 mg....After completing the whole study patient accrual, ORR was 21% (five PRs, confirmed in all cases; Fig 1 and Appendix Figs A1 and A2, online only). Median DoR was 5.82 months (95% CI, 4.24 to 10.76). DCR was 62.5% (five PRs + 10 SDs), and PD was the best response in nine cases (37.5%)....In conclusion, abiraterone in association with LHRH analog is active as second-line in AR-expressing, castrate-resistant SGCs.
Secondary therapy:
prednisone
DOI:
10.1200/JCO.21.00468
Trial ID: